(a ) The number of sleep bouts during the day is increased in misaligned mice, decreased at night, and unchanged between groups when considered over 24 hr (total).
The mortality rate was not significantly different between the groups when considering the longer term data of the SOS trial (OR 1.92 [0.17–21.33], p = 0.597, heterogeneity: I2 = 75%, p = 0.019).
Figure 3 shows, respectively, the comparison between both groups when considering Harris Hip Scores and visual analog pain scales (VAS) collected at days 30, 60, and 90 (HHS, 49.8 versus 43.4/78.5 versus 73.5/8 3.1versus 81.1; VAS, 3.4 versus 4.8/2.2 versus 3.1/1.9 versus 2.1).
Similarly, this 24-month probability was not different between the two groups when considering death and SAEs combined (27.0% vs. 40.7% respectively, Log-rank test, p = 0.08).
A correlation is found between the actual electroactivity and the nature of the functional group, when considered together with the chemical structure of the molecule.
Although both groups reported improvement there was no significant between group difference when considering changes in either of the symptom measures used, nor for any individual symptoms or QoL outcomes (Table 4).
Although no single metabolite was exclusively present in any retinoblastoma group, metabolite concentrations showed consistent differences between groups, and when considered in combination, provided group-specific profiles.
Therefore, we were not able to control for pubertal development in our analysis, which may have implications for our final conceptual model and the characteristics and distinctions between risk groups, particularly when considering the prevalence of prediabetes.
